| Previous Close | 118.67 |
| Open | 118.60 |
| Bid | 0.02 x 100 |
| Ask | 250.06 x 100 |
| Day's Range | 116.61 - 119.60 |
| 52 Week Range | 96.52 - 192.94 |
| Volume | 444,133 |
| Avg. Volume | 1,066,340 |
| Market Cap | 6.45B |
| Beta | 2.31 |
| PE Ratio (TTM) | -11.96 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks•yesterday
Cancer Space Update: Mixed Week for Pfizer, Roche Falters
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
- Zacks•3 days ago
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
- Zacks•5 days ago
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
